natgillin/translations-raw huggingface dataset:
A polymer washout solvent according to one of the preceding claims 1-6, wherein the alcoholic hydrocarbon component comprises a compound chosen from the group of C3-C6 alcoholic compounds or a mixture thereof, contains a primary alcoholic group, and wherein preferably the hydrocarbon chain is straight. 
Otapalo za ispiranje polimera prema jednom od prethodnih zahtjeva 1-5, naznačeno time da alkoholna komponenta ugljikovodika sadrži spoj odabran iz skupine C3-C6 alkoholnih spojeva ili njihovih smjesa, te sadrži primarnu alkoholnu skupinu, a pri čemu je poželjno ugljikovodik ravnolančani.
The pharmaceutical composition of claim 1, wherein said adherent material is selected from the group consisting of a polyester, a polyalkylene, a polyfluorochloroethylene, a polyvinyl chloride, and a polysulfone. 
pri čemu navedeni uvjeti trodimenzionalnog kultiviranja sadrže bioreaktor odabran iz skupine koju čine bioreaktor s klipnim strujanjem, bioreaktor sa neprekidno miješanim spremnikom i bioreaktor sa stacionarnim slojem; i/ili
ring D is selected from wherein, both of A1 and A2 are C or N; 
prsten D je izabran od [image] i [image] gdje su, oba od A1 i A2 jednaki C ili N;
The ingredients of part A were mixed with the exception of the Pemulen and allantoin. 
Sastojci dijela A se pomiješaju uz izuzetak Pemulena i alantoina.
The kit according to claim 11, wherein said N—(N-acetylcysteinyl-)chitosan or pharmaceutically acceptable salt thereof contained therein has a content of free thiol groups of from about 80 umol/g polymer to 250 umol/g polymer after being stored for at least 12 months at room temperature. 
Spremnik prema bilo kojem od zahtjeva 11 do 15, naznačen time da naveden N-(N-acetilcisteinil-)kitozan sadržan u istome ima sadržaj slobodnih tiol grupa od 80 µmol/g polimera do 250 µmol/g polimera, poželjno 105 µmol/g polimera do 250 µmol/g polimera, nakon što je pohranjen barem 12 mjeseci na sobnoj temperaturi.
Thus the invention provides a process for preparing an influenza vaccine from influenza virus that has been grown in a culture of an MDCK cell line, comprising a step in which seed virus and/or the vaccine and/or the culture is tested for the presence of an infectious agent that can grow in said cell line but that does not grow in embryonated hen eggs, wherein said infectious agent is one or more of the following pathogens: mammalian Reoviridae; Pneuomoviridae; Pneumoviruses of the Pneuomoviridae; Morbilliviruses of the Paramyxoviridiae family; Echoviruses of the Enteroviruses of the Picornaviridae family; or Rotavirus. 
PATENTNI ZAHTJEVI L ll. Postupak za pripremanje cjepiva protiv gripe iz virusa gripe izraslog u kulturi MDCK stanične linije, koji sadrži stupanj u kojem se uzgojeni virus i/ili cjepivo i/ili kultura testira na prisutnost infekcijskog agensa koji može rasti u navedenoj staničnoj liniji, ali koji ne raste u embriju kokošjih jaja, naznačen time, da je navedeni infekcijski agens jedan ili više od sljedećih patogena: Reoviridae kod sisavaca; Pneumoviridae; Pneumovirusi od Pneumoviridae;
The adhesion of the U937-monocyte cells to confluent human microvasculature endothelial cells (HMEC-1) activated by means of TNF-a (50 ng/ml) and the platelets to human umbilical endothelial cells (HUVEC) were the methods used to determine the inhibitory effect of compounds on cellular adhesion. 
HR P20090152 T3 Adhezija U937-monocitnih stanica na konfluentne humane mikrovaskularne endotelne stanice (HMEC-1) aktivirane s TNF-a (50 ng/ml) i trombocita na humane umbilikalne endotelne stanice (HUVEC) su bile metode za određivanje inhibitorskog učinka spojeva na staničnu adheziju.
The compound or pharmacologically acceptable salt thereof according to claim 1, wherein X1 is -CH=CH-. 
Spoj ili njegova farmakološki prihvatljiva sol u skladu s patentnim zahtjevom 1, naznačen time, da X1 je -CH=CH-.
Therapeutic substance combination product containing at least one connexin-blocking agent and an acetylcholinesterase inhibitor (AChEI), as combination products for simultaneous, separate or sequential use, for treating cognitive disorders, wherein said acetylcholinesterase inhibitor (AChEI) is donepezil or a pharmaceutical salt thereof. 
Terapijski kombinacijski produkt tvari koji sadrži najmanje jedno sredstvo koje blokira koneksin i inhibitor acetilkolinesteraze (AChEI), kao kombinacijske produkte za simultanu, odvojenu ili sekvencijalnu upotrebu, za liječenje kognitivnih poremećaja, pri čemu rečeni inhibitor acetilkolinesteraze (AChEl) jest donepezil ili njegova farmaceutska sol.
The oral suspension according to claim 18, wherein the solvent is an aqueous solvent. 
Oralna suspenzija u skladu sa zahtjevom 12, naznačena time, da je otapalo vodeno otapalo.
The ASM for use of claim 10, wherein said ASM is recombinant human ASM (rhASM). 
KSM za uporabu u skladu s patentnim zahtjevom 10, pri čemu je navedena KSM rekombinantna ljudska KSM (rhKSM).
The pharmaceutically acceptable liquid composition of any one of claims 1 to 6, formulated for continuous subcutaneous, transdermal, intraduodenal or intravenous administration. 
Farmaceutski prihvatljiv tekući sastav iz bilo kojeg zahtjeva 1 do 6, formuliran za kontinuiranu subkutanu, transdermalnu, intrađuodenalnu ili intravenoznu primjenu.
The tablet as claimed in claim 1, said tablet comprising at least one binder selected from the group comprising hydroxypropyl cellulose, hydroxypropylmethyl cellulose or polyethylene glycol; at least one diluent selected from the group comprising microcrystalline cellulose, mannitol, isomaltose or sorbitol; at least one disintegrating agent selected from the group comprising crospovidone or sodium croscarmellose; at least one lubricant selected from the group comprising Ca stearate, Mg stearate or sodium stearyl fumarate and at least one glidant selected from the group comprising anhydrous colloidal silica or talc. 
Tableta prema zahtjevu 1, naznačena time, da navedena tableta obuhvaća najmanje jedno vezivo odabrano iz skupine koju čine hidroksipropilceluloza, hidroksipropilmetilceluloza ili polietilenglikol; najmanje jedan razrjeđivač odabran iz skupine koju čine mikrokristalna celuloza, manitol, izomaltoza ili sorbitol; najmanje jedan dezintegrator odabran iz skupine koju čine krospovidon ili natrij-kroskarmeloza; najmanje jedno mazivo odabrano iz skupine koju čine Ca-stearat, Mg-stearat, natrijev stearilfumarat; te najmanje jedno klizno sredstvo odabrano iz skupine koju čine bezvodni koloidni silicijev dioksid ili talk.
culturing the epithelial stem cell, population of epithelial stem cells or tissue fragment in a first expansion medium; continuing to culture the epithelial stem cell, population of epithelial stem cells or tissue fragment and replenishing the medium with a differentiation medium, wherein the differentiation medium does not comprise one or more of, preferably all of the factors selected from: a TGF-beta inhibitor, a p38 inhibitor, nicotinamide and Wnt. 
kultiviranje epitelne matične stanice, populacije epitelnih matičnih stanica ili fragmenta tkiva u prvom mediju za proširenje; nastavljanje kultiviranja epitelne matične stanice, populacije epitelnih matičnih stanica ili fragmenta tkiva i dopunjavanje s medijem za diferencijaciju, pri čemu medij za diferencijaciju ne sadrži jedan ili više, poželjno sve faktore koji se biraju od: inhibitora TGF-beta, inhibitora p38, nikotinamida i Wnt.
A method for treatment of breast cancer, ovarian cancer, prostate cancer, colorectal cancer, mesothelioma and other sarcomas, neuroblastoma, lymphoma, leukaemia or melanoma, comprising providing and applying an effective amount of the antitumoral agent according to claim 10 in a patient in need thereof. 
Spoj formule (I) ili njegova farmaceutski prihvatljiva sol za upotrebu prema patentnom zahtjevu 11 u liječenju karcinoma dojke, karcinoma jajnika, karcinoma prostate, kolorektalnog karcinoma, mezotelioma i drugih sarkoma, neuroblastoma, limfoma, leukemije i melanoma.
the coding unit determiner (120) generates the information about a size of a transformation unit of the coding unit of the coded depth, wherein at least one transformation unit are obtained from the coding unit of the current depth according to the size of a transformation unit and inverse transformation is performed on the coding unit of the current depth based on the at least one transformation unit. A non-transitory computer-readable storage medium storing a bitstream, the bitstream comprising: 
HR P20182053 T1 određivač jedinice za kodiranje (120) generira informaciju o veličini jedinice za transformaciju od jedinice kodiranja dubine kodiranja, pri čemu se dobiva barem jedna jedinica za transformaciju, prema veličini transformacijske jedinice, dijeljenjem visine i širine jedinice kodiranja trenutne dubine ili da podatkovna jedinica bude iste veličine kao jedinica kodiranja trenutne dubine 1 transformacija se izvršava na jedinici kodiranja trenutne dubine temeljeno na barem jednoj transformacijskoj jedinici.
the infection is caused by an organism resistant to tetracycline; 
(n) infekcija je uzrokovana organizmom otpornim na tetraciklin;
Gram-Negative bacteria selected from Gram negative bacteria of enterobacteria e.g E. coli, Klebsiella, Serratia, Enterobacter, Citrobacter, Morganella, Providencia or Proteus; 
– Gram-negativnim bakterijama koje se bira između Gram-negativnih bakterija iz skupine enterobakterija primjerice E. coli, Klebsiella, Serratia, Enterobacter, Citrobacter, Morganella, Providencia ili Proteus;
high performance liquid chromatography conc. = 
= tekućinska kromatografija visokog učinka conc.
Anti-inflammatory agents selected from: nonsteroidal anti-inflammatory agents selected from piroxicam, diclofenac, propionic acids, fenamates, pyrazolones, salicylates, PDE-4/pd38 MAP Kinase/Cathepsin inhibitors; (ii) leukotrienes, LTC4/LTD4/LTE4/LTB4-Inhibitors, 5-lipoxygenase inhibitors and PAF receptor antagonists; (iii) Cox-2 inhibitors; (iv) MMP inhibitors; or 
Protuupalna sredstva odabrana između sljedećeg: nesteroidna protuupalna sredstva odabrana između piroksikama, diklofenaka, propionskih kiselina, fenamata, pirazolona, salicilata, inhibitora PDE-4/pd38 MAP kinaze/katepsina; leukotriena, inhibitora LTC4/LTD4/LTE4/LTB4, inhibitora 5-lipoksigenaze i antagonista receptora PAF;
A system as claimed in claim 1, wherein the at least one stimulating device is a pre-cabled helmet or a cap with a precise location of the at least two electrodes. 
Sistem kao u patentnim zahtjevima 1 ili 2 gdje je najmanje jedan uređaj za stimulaciju kaciga ili kapa prethodno povezana putem kabela sa preciznom lokacijom najmanje dvije elektrode.
The compounds of the invention were tested according to the following methods: 
Spojevi naznačeni ovim izumom su ispitivanu prema sljedećim postupcima:
Disorders of this type that would be expected to be amenable to treatment with the compounds of the invention include but are not limited to cancers, including leukemia, skin cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, prostate cancer, lung cancer, colon cancer, pancreatic cancer, renal cancer, gastric cancer and brain cancer; restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis and kidney disease. 
Pripravak za uporabu prema zahtjevu 13 naznačen time da navedena bolest ili poremećaj povezan s PI3K je poremećaj proliferacije stanice, poželjno gdje je poremećaj proliferacije stanice rak, kao što je papilom, blastogliom, Kapozijev sarkom, melanom, karcinom ne-malih stanica pluća, rak jajnika, rak prostate, karcinom skvamoznih stanica, astrocitom, rak glave, rak vrata, rak mokraćnog mjehura, rak dojke, rak pluća, kolorektalni rak, rak tiroidne žlijezde, rak gušterače, rak želuca, hepatocelularni karcinom, leukemija, limfom, Hodgkinova bolest i
The use of claim 19, wherein the second therapeutic agent is quinidine sulfate. The use of claim 19 or 20, wherein the dosage amount of the compound of Formula I or pharmaceutically acceptable salt thereof is 10-60 mg, and the dosage amount of quinidine is 2.5-30 mg. 
Uporaba u skladu s patentnim zahtjevom 20 ili 21, pri čemu je drugi terapijski agens kinidin, i pri čemu je količina doziranja tvari formule I ili njene farmaceutski prihvatljive soli 10-60 mg, a količina doziranja kinidina je 2.5-30 mg.
The antibody of claim 7, wherein at least 20% to 50% of the N-linked oligosaccharides in the Fc region are bisected, nonfucosylated. 
Protutijelo u skladu sa zahtjevom 7, naznačeno time, da su najmanje 20% do 50% N-vezanih oligosaharida u Fc regiji prepolovljeni, nefukozilirani.
is cycloalkyl, aryl, heteroaryl or heterocyclyl substituted with 0-5 occurrences of Rd, or 
Tvar iz patentnog zahtjeva 6, pri čemu je R1 cikloalkil, aril, heteroaril i heterociklil s 0-5 pojavljivanja Rd.
Centrifuging said tube, and 
Centrifugiranje navedene epruvete i
Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations and conditions without departing from the spirit and scope of the invention and without undue experimentation. 
Kada smo potpuno opisali izum, biti će korisno za stručnjake da se isti može provesti u rasponu podjednakih parametara, koncentracija i uvjeta koji ne ovise o okvirima ovoga izuma bez nepotrebnog dodatnog eksperimentiranja.
A compound of formula (Ic): 
Spoj formule (Ic):
It is a specific object of this invention to provide a new stable formulation of ET-743. 
Poseban cilj ovog izuma je osigurati novi stabilni oblik ET-743.
A river boat for carrying passengers according to claim 2, wherein said forward facing wall (15) is curved in shape. 
Riječni brod za prijevoz putnika sukladno patentnom zahtjevu 2, naznačeno time, da se spomenuta stijenka okrenuta prema naprijed (15) ima zakrivljen oblik.
The antibody or antigen-binding fragment according to claim 1, wherein the binding of the antibody or fragment thereof to a variant PCSK9 protein is less than 50% of the binding between the antibody or fragment thereof and the PCSK9 protein of SEQ ID NO:755; optionally wherein the variant PCSK9 protein comprises at least one mutation of a residue at a position selected from the group of, E159, D238 and D343. 
Antitijelo ili njegov fragment koji veže antigen u skladu s patentnim zahtjevom 1, naznačeno time, da je vezanje antitijela ili njegovog fragmenta na varijantu PCSK9 proteina manje od 50 % vezanja između antitijela ili njihovih fragmenata i PCSK9 proteina SEQ ID NO:755; pri čemu po izboru varijanta PCSK9 proteina sadržava najmanje jednu mutaciju ostatka na položaju odabranom iz skupine koju čine S153, E159, D238 i D343.
reacting the amine of formula 2c with an acid of formula 1d to provide a compound of Formula (Ic) 
(c) reakciju amina sa formulom 2c sa kiselinom sa formulom 1d da se dobije spoj sa Formulom (Ic)
each -R1D6, if present, is independently pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, or tetrahydropyranyl, and is optionally substituted; 
svaki -R1D6, ako je prisutan, tada je neovisno pirolidinil, piperidinil, piperazinil, morfolinil, tetrahidrofuranil, ili tetrahidropiranil, i opcijski je supstituiran;
A counter as claimed in claim 18, wherein said third ring member comprises a limiting mechanism to limit free rotation of said second ring member relative to said third ring member about said common axis. 
Brojač kao što je navedeno u zahtjevu 15, naznačeno time da navedeni treći prstenasti element (1502) sadrži mehanizam ograničenja (1506) za ograničavanje slobodne rotacije navedenog drugog prstenastog elementa (202, 1510) u odnosu na navedeni treći prstenasti element oko navedene zajedničke osi.
A compound for use according to any of claims 1 to 5, wherein the plasma Cmax value of dexmedetomidine in the subject animal is from 0.05 to 0.8 ng/ml, preferably from 0.15 to 0.6 ng/ml. 
Spoj za primjenu prema bilo kojem zahtjevu od 1 do 5, naznačen time što vrijednost Cpnax deksmedetomidina u plazmi kod predmetne životinje iznosi od 0,05 do 0,8 ng/ml, poželjno od 0,15 do 0,6 ng/ml.
Subsequently, forming a second solution in water for injection by adding at least one osmotic agent, a tonicity agent, a suspending agent, a chelating agent and a preservative agent and mixing until complete homogeneity; 
Naknadno, formiranje druge otopine u vodi za injekciju dodavanje barem jednog osmotskog sredstva, sredstva za toničnost, sredstva za suspenziju, kelatnog sredstva i konzervansa i miješanje do potpuno homogenosti;
A compound according to claim 73 of formula (VB) 
Spoj u skladu s patentnim zahtjevom 73 formule (V?) s
The speech decoding device according to claim 1, wherein the secondary high frequency adjuster executes, on the output signal generated by the temporal envelope shaper the addition of sinusoids in spectral band replication (SBR) decoding. 
Naprava za dekodiranje govora u skladu s patentnim zahtjevom 1 ili 2, naznačena time što sekundarni visokofrekventni podešavač obrađuje izlazni signal, kojeg generira generator vremenske ovojnice, dodavanjem sinusoida kod SBR dekodiranja.
At its top end the line section 32 is provided with a pull lip or ring 46 to detach the line section 32 from engagement means fixed to the lid 5 of the chill chamber 2. 
Na svojem gornjem kraju dio cijevi 32 ima potezni izdanak ili prsten 46 kojim se može odvojiti dio cijevi 32 od zahvatnog dijela koji je pričvršćen na poklopac 5 hladne komore 2.
The scaffold of claim 11, wherein said polymer coating is present at a terminus of said scaffold and said coating has a thickness of between about 0.1-10 mm. The scaffold of claim 11, wherein said polymer is in the form of a hydrogel. 
Struktura platforme sukladno patentnom zahtjevu 12, pri čemu je navedeni polimerni oblog prisutan na terminusu navedene strukture platforme i navedeni oblog je debljine od između 0,1 -10 mm.
In a particular embodiment, the sugar stabiliser is selected from the group including trehalose, mannitol, sucrose, maltose, lactose, xylitol, arabitol, erythritol, lactitol, maltitol, inositol. 
Vodeni farmaceutski pripravak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da je stabilizator šećera šećerni alkohol odabran iz skupine sastavljene iz sorbitola, ksilitola, arabitola, eritritola, laktitola, maltitola i inozitola.
A salt of formula I, or a solvate thereof. 
Sol formule I, ili njen solvat.
The sclerostin-binding antibody of any one of the preceding claims, wherein said antibody has a binding affinity (Kd) for human sclerostin of less than or equal to 1 x 10-9 M, less than or equal to 1 x 10-10 M, less than or equal to 1 x 10-11 M, or less than or equal to 1 x 10-12 M. 
Protutijelo za vezanje sklerostina iz bilo kojeg od prethodnih patentnih zahtjeva, naznačeno time, da navedeno protutijelo ima disocijacijsku konstantu za humani sklerostin izmjerenu površinskom plazmonskom rezonancijom manjom od ili jednakom 1 × 10-9 M, manjom od ili jednakom 1 × 10-10M, manjom od ili jednakom 1 × 10-11M ili manjom od ili jednakom 1 ×10-12 M.
The matrix materials may be present in different crosslinked forms, depending on the specific use. 
Materijal za matriks može biti prisutan u različitim izmiješanim oblicima što ovisi o specifičnoj uporabi.
The method according to claim 1, wherein SAMe or its salts is present in a quantity of between approximately 30% and approximately 90% by weight calculated in relation to the weight of the composition. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što se oblaganje spomenuto u koraku e) primijenjuje upotrebom hidrogeniranih masnih kiselina u količini između 0,4 i 1,5%, težinski, u odnosu na težinu tablete.
providing a boron "ate" complex of formula (XV): wherein: 
(a) osiguravanje kompleksa borata formule (XV):
The extracted coffee flows through the orifices of the flow grill 112 and is recovered in a container (not shown) beneath the bore 127. 
Istočena kava protječe kroz otvore na protočnoj rešetki 112 i skuplja sc u spremnik (nije prikazan) koji sc nalazi ispod otvora 127.
wherein the induction heating element receives an alternating current from the power source and creates an electromagnetic induction field around the wick element, and wherein the wick element generates heat based on the electromagnetic induction field. 
pri čemu indukcijski grijaći element (121) zaprima izmjeničnu struju i stvara elektromagnetsko indukcijsko polje oko fitilja (400, 500, 600), te time, da fitilj (400, 500, 600) proizvodi toplinu na bazi elektromagnetskog indukcijskog polja.
wherein said cancer is a cardiac cancer selected from the group consisting of: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma; 
gdje naveden tumor predstavlja tumor srca izabran iz grupe koja se sastoji od: sarkoma (angiosarkoma, fibrosarkoma, rabdomiosarkoma, liposarkoma), miksoma, rabdomioma, fibroma, lipoma, i teratoma;
a CDR1-H of sequence SEQ ID NO:25 or a sequence differing from SEQ ID NO:25 by one amino acid substitution; CDR2-H of sequence SEQ ID NO:26 or a sequence differing from SEQ ID NO:26 by one or more amino acid substitutions; CDR3-H of sequence SEQ ID NO:27 or a sequence differing from SEQ ID NO:27 by one or more amino acid substitutions; CDR1-L of sequence SEQ ID NO:28 or a sequence differing from SEQ ID NO:28 by one amino acid substitution; CDR2-L of sequence NAK or a sequence differing from NAK by one or more amino acid substitutions and CDR3-L of sequence SEQ ID NO:30 or a sequence differing from SEQ ID NO:30 by one amino acid substitution. 
CDR1-H od sekvence SEQ ID NO:25 ili sekvencu koja se razlikuje od SEQ ID NO:25 po supstituciji jedne aminokiseline; CDR2-H od sekvence SEQ ID NO:26 ili sekvencu koja se razlikuje od SEQ ID NO:26 po supstitucijama jedne ili više aminokiselina; CDR3-H od sekvence SEQ ID NO:27 ili sekvencu koja se razlikuje od SEQ ID NO:27 po supstitucijama jedne ili više aminokiselina; CDR1-L od sekvence SEQ ID NO:28 ili sekvencu koja se razlikuje od SEQ ID NO:28 po supstituciji jedne aminokiseline; CDR2-L od sekvence NAK ili sekvencu koja se razlikuje od NAK po supstitucijama jedne ili više aminokiselina i CDR3-L od sekvence SEQ ID NO:30 ili sekvencu koja se razlikuje od SEQ ID NO:30 po supstituciji jedne aminokiseline.
generating a warning message or signal if the displacement exceeds a predetermined alarm threshold. 
(b) generiranje poruke upozorenja ili signala ako pomak prelazi predodređenu razinu aktiviranja alarma.
The invert arm assembly of claim 26 in which the idler gear mounting shaft that includes a pair of opposed adjustment screws (94) and the shaft on which the idler gear is mounted which is movable relative to the mounting shaft and wherein the position of shaft on which the idler gear is mounted relative to said mounting shaft can be maintained by manipulation of said adjustment screws. 
Sklop invertirajuće ruke iz zahtjeva 26 u kojem je potporni zupčanik montiran na osovinu koja uključuje par suprotnih vijaka za podešavanje (94) te je osovina na koju je potporni zupčanik montiran i može se pomicati u odnosu na tu osovinu i naznačen time da položaj osovine na koju je montiran potporni zupčanik može biti podešavan pomoću spomenutih vijaka za podešavanje.
The reaction crude is poured over 100 mL of water, filtered and washed with plenty of water. 
Sirovu reakcijsku smjesu se prelije na 100 mL vode, profiltrira i ispere s mnogo vode.
at least one projecting part in the extension of the first flange and comprising an upper plateau with a height H 7 and width L 7 and two lateral webs extending from the upper plateau on either side and downward, forming an angle B with the plane P, 
barem jedan izbočeni dio (6, 6") kao nastavak prvog osnovnog dijela i koji sadrži gornju plohu (7) visine H7 i širine 1.7 i dva bočna dijela rebra (8, 8) koja produžuju gornju plohu nje njezine obje strane i prema dolje, tvore kut fB s ravninom P, -